Geneva, Aug. 17 -- International Clinical Trials Registry received information related to the study (ChiCTR2600129680) titled 'Real-World Study on the Efficacy and Safety of Inetetamab Combined with Chemotherapy for HER2-Positive Advanced Breast Cancer' on Aug. 7.
Study Type: Observational study
Study Design:
Sequential
Primary Sponsor: Tianjin Medical University Cancer Institute and Hospital
Condition:
HER2-positive breast cancer
Recruitment Status: Recruiting
Phase: N/A
Date of First Enrollment: 2025-05-16
Target Sample Size: Inetetamab treatment group:107;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=281677
Published by HT Digital Content Services with permission from...